Here’s some Martin Shkreli news
Four years after Turing Pharmaceuticals famously raised the price of a generic drug (and two years after its founder was sentenced to federal prison), the company is getting sued for manufacturing a monopoly.
As STAT’s Ed Silverman reports, the Federal Trade Commission and the New York attorney general claim that Turing and ex-CEO Martin Shkreli broke the law by blocking generics companies from launching competitors to the costly Daraprim, which treats a serious parasitic infection.
In the meantime, Turing has changed its name first to Vyera and since to Phoenixus, and Shkreli is two years into a seven-year bid from an unrelated securities fraud conviction. Shkreli still maintains a controlling interest in the company, and Phoenixus is still in the business of selling Daraprim, albeit with diminishing returns.
Read more.
As STAT’s Ed Silverman reports, the Federal Trade Commission and the New York attorney general claim that Turing and ex-CEO Martin Shkreli broke the law by blocking generics companies from launching competitors to the costly Daraprim, which treats a serious parasitic infection.
In the meantime, Turing has changed its name first to Vyera and since to Phoenixus, and Shkreli is two years into a seven-year bid from an unrelated securities fraud conviction. Shkreli still maintains a controlling interest in the company, and Phoenixus is still in the business of selling Daraprim, albeit with diminishing returns.
Read more.
No hay comentarios:
Publicar un comentario